Collegium Pharmaceutical saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an upgrade from 64 to 76.
Can You Really Time The Stock Market?
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains typically have an 80 or better RS Rating in the early stages of their moves. See if Collegium Pharmaceutical can continue to show renewed price strength and clear that threshold.
Collegium Pharmaceutical is working on a cup without handle with a 42.29 buy point. See if the stock can break out in volume at least 40% higher than normal.
Collegium Pharmaceutical saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 3% to 4%. Revenue rose from 23% to 29%.
Collegium Pharmaceutical earns the No. 1 rank among its peers in the Medical-Generic Drugs industry group. Collegium Pharmaceutical and Dr. Reddy's Labs ADR are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
